title: Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice.
abstract: To study the antitumor activity of the combination immunotherapy with interleukin-12 (IL-12) and granulocyte-macrophage colony-stimulating factor (GM-CSF), a murine MmB 16 melanoma tumor model was used. Seven days after inoculation of MmB 16 melanoma cells into the footpad of the right hind limb, mice were treated with IL-12 and/or GM-CSF administered intratumorally for 7 consecutive days. IL-12 used both at a high (1 microg) and at a low (0.01 microg) dose per day produced retardation of tumor growth, although neither treatment resulted in any significant prolongation of the survival of tumor-bearing mice. GM-CSF did not by itself exert antitumor activity in this model; however, it potentiated antitumor effects of IL-12. In particular, survival of tumor-bearing mice treated with IL-12 (0.01 microg per day) and GM-CSF was significantly prolonged compared with that in mice treated with either IL-12 or GM-CSF alone.
authors.affiliation: Department of Immunology, Institute of Biostructure, Medical School of Warsaw, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Gołab
authors.forename: T
authors.initials: T
authors.lastname: Stokłosa
authors.forename: R
authors.initials: R
authors.lastname: Zagozdzon
authors.forename: A
authors.initials: A
authors.lastname: Kaca
authors.forename: L A
authors.initials: LA
authors.lastname: Kulchitska
authors.forename: W
authors.initials: W
authors.lastname: Feleszko
authors.forename: J
authors.initials: J
authors.lastname: Kawiak
authors.forename: G
authors.initials: G
authors.lastname: Hoser
authors.forename: E
authors.initials: E
authors.lastname: Głowacka
authors.forename: A
authors.initials: A
authors.lastname: Dabrowska
authors.forename: A
authors.initials: A
authors.lastname: Giermasz
authors.forename: W
authors.initials: W
authors.lastname: Lasek
authors.forename: M
authors.initials: M
authors.lastname: Jakóbisiak
mesh_terms: D000818:Animals; D002455:Cell Division; D002470:Cell Survival; D004357:Drug Synergism; D004906:Erythrocyte Count / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006614:Hindlimb; D018664:Interleukin-12 / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000187:drug effects; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000502:physiology; D008546:Melanoma, Experimental / Q000097:blood / Q000473:pathology / Q000628:therapy*; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D009929:Organ Size / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D013154:Spleen / Q000187:drug effects; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D018664:Interleukin-12; D009569:Nitric Oxide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor